Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Infectious disease; respiratory syncytial virus (RSV)

Metapneumovirus
F protein; RSV
F protein

Cell culture and mouse studies suggest the human mAb MPE8 could help treat or prevent RSV and metapneumovirus (MPV) infection. The antibody was isolated from immortalized memory B cells obtained from blood donors with high serum neutralizing antibody titers against both viruses. In vitro and in cell culture, MPE8 neutralized RSV and MPV by binding to the prefusion F protein. In a mouse model of RSV infection, MPE8 was 5- to 10-fold more potent than Synagis palivizumab at decreasing virus levels in the lung. Next steps could include a clinical trial of MPE8 in transplant patients who have an upper respiratory tract infection caused by RSV or MPV.
AstraZeneca plc and Abbott Laboratories market Synagis, a humanized mAb against RSV F protein, as a prophylactic for RSV infection.

AstraZeneca's motavizumab, a humanized anti-RSV F protein mAb, is in Phase III trials as a prophylactic for RSV infection.

SciBX 6(36); doi:10.1038/scibx.2013.997
Published online Sept. 19, 2013

Patent application filed; available for licensing through Humabs BioMed S.A.

Corti, D. et al. Nature; published online Aug. 18, 2013;
doi:10.1038/nature12442
Contact: Antonio Lanzavecchia, University of Lugano,
Bellinzona, Switzerland
e-mail:

lanzavecchia@irb.usi.ch
Contact: Davide Corti, Humabs BioMed S.A., Bellinzona, Switzerland
e-mail:

davide.corti@humabs.ch